Literature DB >> 18525005

Overexpression of calmodulin in pancreatic beta cells induces diabetic nephropathy.

Yukio Yuzawa1, Ichiro Niki, Tomoki Kosugi, Shoichi Maruyama, Futoshi Yoshida, Motohiro Takeda, Yoshiaki Tagawa, Yukiko Kaneko, Toshihide Kimura, Noritoshi Kato, Jyunichiro Yamamoto, Waichi Sato, Takahiko Nakagawa, Seiichi Matsuo.   

Abstract

Recently, endothelial dysfunction induced by an uncoupling of vascular endothelial growth factor (VEGF) and nitric oxide has been implicated in the pathogenesis of diabetic nephropathy (DN). Investigating the pathogenesis of DN has been limited, however, because of the lack of animal models that mimic the human disease. In this report, pancreatic beta cell-specific calmodulin-overexpressing transgenic (CaMTg) mice, a potential new model of DN, are characterized with particular emphasis on VEGF and related molecules. CaMTg mice developed hyperglycemia at 3 wk and persistent proteinuria by 3 mo. Morphometric analysis showed considerable increases in the glomerular and mesangial areas with deposition of type IV collagen. Moreover, the pathologic hallmarks of human DN (mesangiolysis, Kimmelstiel-Wilson-like nodular lesions, exudative lesions, and hyalinosis of afferent and efferent arteries with neovascularization) were observed. In addition, increased VEGF expression was associated with an increased number of peritubular capillaries. Expression of endothelial nitric oxidase synthase was reduced and that of VEGF was markedly elevated in CaMTg mice kidney compared with nontransgenic mice. No differences in VEGF receptor-1 or VEGF receptor-2 expression were observed between CaMTg mice and nontransgenic kidneys. In summary, CaMTg mice develop most of the distinguishing lesions of human DN, and the elevated VEGF expression in the setting of diminished endothelial nitric oxide synthase expression may lead to endothelial proliferation and dysfunction. This model may prove useful in the study of the pathogenesis and treatment of DN.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18525005      PMCID: PMC2518429          DOI: 10.1681/ASN.2006121358

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  42 in total

1.  Diabetic nephropathy: Linking histology, cell biology, and genetics.

Authors:  Sharon Adler
Journal:  Kidney Int       Date:  2004-11       Impact factor: 10.612

2.  Determination of membrane thickness distribution from orthogonal intercepts.

Authors:  E B Jensen; H J Gundersen; R Osterby
Journal:  J Microsc       Date:  1979-01       Impact factor: 1.758

3.  Calmodulin-induced early-onset diabetes in transgenic mice.

Authors:  P N Epstein; P A Overbeek; A R Means
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

Review 4.  On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship.

Authors:  J E Sealey; J D Blumenfeld; G M Bell; M S Pecker; S C Sommers; J H Laragh
Journal:  J Hypertens       Date:  1988-10       Impact factor: 4.844

5.  Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.

Authors:  D Koya; M Haneda; H Nakagawa; K Isshiki; H Sato; S Maeda; T Sugimoto; H Yasuda; A Kashiwagi; D K Ways; G L King; R Kikkawa
Journal:  FASEB J       Date:  2000-03       Impact factor: 5.191

6.  Antibody-mediated redistribution and shedding of endothelial antigens in the rabbit.

Authors:  Y Yuzawa; J R Brentjens; J Brett; P R Caldwell; C Esposito; A Fukatsu; G Godman; D Stern; G Andres
Journal:  J Immunol       Date:  1993-06-15       Impact factor: 5.422

Review 7.  The role of vascular endothelial growth factor (VEGF) in renal pathophysiology.

Authors:  Bieke F Schrijvers; Allan Flyvbjerg; An S De Vriese
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

8.  Elevated beta-cell calmodulin produces a unique insulin secretory defect in transgenic mice.

Authors:  P N Epstein; T J Ribar; G L Decker; G Yaney; A R Means
Journal:  Endocrinology       Date:  1992-03       Impact factor: 4.736

Review 9.  Remission and regression of diabetic nephropathy.

Authors:  Hirofumi Makino; Yoshio Nakamura; Jun Wada
Journal:  Hypertens Res       Date:  2003-07       Impact factor: 3.872

10.  Hemodynamically mediated glomerular injury and the progressive nature of kidney disease.

Authors:  B M Brenner
Journal:  Kidney Int       Date:  1983-04       Impact factor: 10.612

View more
  9 in total

Review 1.  Modelling diabetic nephropathy in mice.

Authors:  Kengo Azushima; Susan B Gurley; Thomas M Coffman
Journal:  Nat Rev Nephrol       Date:  2017-10-24       Impact factor: 28.314

2.  Metabolomic Analysis of Serum and Tear Samples from Patients with Obesity and Type 2 Diabetes Mellitus.

Authors:  Erdenetsetseg Nokhoijav; Andrea Guba; Ajneesh Kumar; Balázs Kunkli; Gergő Kalló; Miklós Káplár; Sándor Somodi; Ildikó Garai; Adrienne Csutak; Noémi Tóth; Miklós Emri; József Tőzsér; Éva Csősz
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

3.  Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse.

Authors:  Nina Reiniger; Kai Lau; Daren McCalla; Bonnie Eby; Bin Cheng; Yan Lu; Wu Qu; Nosirudeen Quadri; Radha Ananthakrishnan; Maryana Furmansky; Rosa Rosario; Fei Song; Vivek Rai; Alan Weinberg; Richard Friedman; Ravichandran Ramasamy; Vivette D'Agati; Ann Marie Schmidt
Journal:  Diabetes       Date:  2010-07-13       Impact factor: 9.461

4.  Diabetic albuminuria is due to a small fraction of nephrons distinguished by albumin-stained tubules and glomerular adhesions.

Authors:  Patricia M Kralik; Yunshi Long; Ye Song; Lu Yang; Haiyang Wei; Susan Coventry; Shirong Zheng; Paul N Epstein
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

5.  Distribution of hydrogen sulfide (H₂S)-producing enzymes and the roles of the H₂S donor sodium hydrosulfide in diabetic nephropathy.

Authors:  Junichiro Yamamoto; Waichi Sato; Tomoki Kosugi; Tokunori Yamamoto; Toshihide Kimura; Shigeki Taniguchi; Hiroshi Kojima; Shoichi Maruyama; Enyu Imai; Seiichi Matsuo; Yukio Yuzawa; Ichiro Niki
Journal:  Clin Exp Nephrol       Date:  2012-08-08       Impact factor: 2.801

6.  Semaphorin3a promotes advanced diabetic nephropathy.

Authors:  Pardeep K Aggarwal; Delma Veron; David B Thomas; Dionicio Siegel; Gilbert Moeckel; Michael Kashgarian; Alda Tufro
Journal:  Diabetes       Date:  2014-12-04       Impact factor: 9.461

Review 7.  Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice.

Authors:  Takamune Takahashi; Raymond C Harris
Journal:  J Diabetes Res       Date:  2014-10-13       Impact factor: 4.011

Review 8.  Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease.

Authors:  Yosuke Hirakawa; Tetsuhiro Tanaka; Masaomi Nangaku
Journal:  J Diabetes Investig       Date:  2017-03-13       Impact factor: 4.232

Review 9.  An Update on the Use of Animal Models in Diabetic Nephropathy Research.

Authors:  Boris Betz; Bryan R Conway
Journal:  Curr Diab Rep       Date:  2016-02       Impact factor: 4.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.